Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma

This study investigated the applicability of personalized peptide vaccination (PPV) for patients with metastatic upper tract urothelial cancer (mUTUC) after failure of platinum‐based chemotherapy. In this single arm, open‐label, phase II clinical trial, patients with mUTUC received PPV at a single i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Suekane, Shigetaka, Ueda, Kousuke, Nishihara, Kiyoaki, Sasada, Tetsuro, Yamashita, Takuto, Koga, Noriko, Yutani, Shigeru, Shichijo, Shigeki, Itoh, Kyogo, Igawa, Tsukasa, Noguchi, Masanori
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5715265/
https://ncbi.nlm.nih.gov/pubmed/28940789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13404
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars